Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
News|Articles|September 1, 2025
Dermatology Conferences and Meetings Calendar: September 2025
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- A list of dermatological meetings for September 2025 has been compiled from reader responses.
- Dermatology professionals have shared their anticipated conferences, highlighting community engagement with upcoming events.
Dermatology Times has compiled a list of dermatological meetings taking place during the month of September.
Advertisement
Dermatology Times has asked our readers to share with us what conferences and meetings they are looking forward to or planning to attend in 2025.
Using these responses, we have compiled a list of dermatological meetings taking place in September.
Interested in sharing what conferences you are interested in or planning to attend this year? Email our team at
September
September 12-13, 2025: Great Lakes Integrated Dermatology Education (GLIDE) Conference
Bloomfield Hills, Michigan
September 17-20, 2025: European Academy of Dermatology and Venereology Congress
Paris, France
September 20-23, 2025: Maui Derm NP+PA Fall
Nashville, Tennessee
September 26-28, 2025: Massachusetts Academy of Dermatology 2025 Annual Conference
Newport, Rhode Island
Advertisement
Related to this article
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
4
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
5